FibroGen (NASDAQ:FGEN – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.
Institutional and Insider Ownership
72.7% of FibroGen shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 2.0% of FibroGen shares are owned by company insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
FibroGen has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| FibroGen | $147.75 million | 0.23 | -$284.23 million | ($1.23) | -0.27 |
| Unicycive Therapeutics | $680,000.00 | 109.07 | -$30.54 million | ($0.97) | -0.74 |
Unicycive Therapeutics has lower revenue, but higher earnings than FibroGen. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares FibroGen and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| FibroGen | -67.66% | N/A | -36.17% |
| Unicycive Therapeutics | N/A | N/A | -29.88% |
Analyst Ratings
This is a breakdown of recent ratings for FibroGen and Unicycive Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| FibroGen | 0 | 1 | 0 | 0 | 2.00 |
| Unicycive Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Unicycive Therapeutics has a consensus price target of $5.13, indicating a potential upside of 617.28%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than FibroGen.
Summary
Unicycive Therapeutics beats FibroGen on 11 of the 14 factors compared between the two stocks.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
